KR102946955B1 - Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제 - Google Patents

Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제

Info

Publication number
KR102946955B1
KR102946955B1 KR1020227018050A KR20227018050A KR102946955B1 KR 102946955 B1 KR102946955 B1 KR 102946955B1 KR 1020227018050 A KR1020227018050 A KR 1020227018050A KR 20227018050 A KR20227018050 A KR 20227018050A KR 102946955 B1 KR102946955 B1 KR 102946955B1
Authority
KR
South Korea
Prior art keywords
alk
cells
ltk
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227018050A
Other languages
English (en)
Korean (ko)
Other versions
KR20220098158A (ko
Inventor
헤소 파르한
루드비그 문테
키예틸 타스켄
시그리드 스콘랜드
마리아세레나 길리베르토
프레드릭 헬름 슈예스볼드
크리스토프 드리센
렌카 베세
안드레이 베세
Original Assignee
유니버시티에트 이 오슬로
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티에트 이 오슬로 filed Critical 유니버시티에트 이 오슬로
Publication of KR20220098158A publication Critical patent/KR20220098158A/ko
Application granted granted Critical
Publication of KR102946955B1 publication Critical patent/KR102946955B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020227018050A 2019-10-28 2020-03-12 Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제 Active KR102946955B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915618A GB201915618D0 (en) 2019-10-28 2019-10-28 ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
GB1915618.1 2019-10-28
PCT/EP2020/056698 WO2021083555A1 (en) 2019-10-28 2020-03-12 Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases

Publications (2)

Publication Number Publication Date
KR20220098158A KR20220098158A (ko) 2022-07-11
KR102946955B1 true KR102946955B1 (ko) 2026-04-02

Family

ID=68768829

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018050A Active KR102946955B1 (ko) 2019-10-28 2020-03-12 Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제

Country Status (9)

Country Link
US (1) US12465607B2 (https=)
EP (1) EP4051288A1 (https=)
JP (1) JP7629228B2 (https=)
KR (1) KR102946955B1 (https=)
CN (1) CN114901289A (https=)
AU (1) AU2020374150B2 (https=)
CA (1) CA3159339A1 (https=)
GB (1) GB201915618D0 (https=)
WO (1) WO2021083555A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230091284A (ko) * 2021-12-16 2023-06-23 부산대학교 산학협력단 Surf4 억제제를 포함하는 혈액암의 예방 또는 치료용 약학적 조성물
WO2024017334A1 (zh) * 2022-07-22 2024-01-25 贝达药业股份有限公司 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
CN115993453B (zh) * 2022-07-22 2025-03-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024059525A2 (en) * 2022-09-12 2024-03-21 Endotarget, Inc. Compounds and methods for the targeted degradation of anaplastic lymphoma kinase and ros1 kinase
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용
CN119700981A (zh) * 2024-12-24 2025-03-28 中南大学湘雅二医院 Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2019113345A1 (en) * 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
WO2019141235A1 (zh) 2018-01-20 2019-07-25 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233963B2 (en) 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
US8904383B2 (en) 2008-04-10 2014-12-02 Hewlett-Packard Development Company, L.P. Virtual machine migration according to environmental data
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
BR112013015000A2 (pt) 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
EP2916841A1 (en) 2012-11-07 2015-09-16 Novartis AG Combination therapy
US10117872B2 (en) 2014-03-28 2018-11-06 Università Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
CN105294649B (zh) 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20170060042A (ko) * 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
JPWO2019039390A1 (ja) 2017-08-25 2020-07-30 国立大学法人東海国立大学機構 若年性骨髄単球性白血病治療薬

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2019113345A1 (en) * 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
WO2019141235A1 (zh) 2018-01-20 2019-07-25 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Also Published As

Publication number Publication date
CA3159339A1 (en) 2021-05-06
JP2022554258A (ja) 2022-12-28
GB201915618D0 (en) 2019-12-11
WO2021083555A1 (en) 2021-05-06
EP4051288A1 (en) 2022-09-07
CN114901289A (zh) 2022-08-12
US20220401444A1 (en) 2022-12-22
AU2020374150B2 (en) 2025-12-18
JP7629228B2 (ja) 2025-02-13
US12465607B2 (en) 2025-11-11
KR20220098158A (ko) 2022-07-11
AU2020374150A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
KR102946955B1 (ko) Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제
Bhansali et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Knudsen et al. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
O'Hare et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia
Hurtz et al. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
Cervantes-Gomez et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia
Cerchietti et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Ren Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
Reynoird et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer
Wang et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia
KR20180033194A (ko) 키랄 디아릴 매크로사이클 및 이것의 용도
Ben-Batalla et al. Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor–sensitive and-resistant chronic myeloid leukemia
Appelmann et al. Janus kinase inhibition by ruxolitinib extends dasatinib-and dexamethasone-induced remissions in a mouse model of Ph+ ALL
JP2012187105A (ja) ＧＳＫ３β阻害効果に基づく抗がん剤の評価方法
Rampal et al. Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms
JP2007526882A (ja) リンパ球性白血病を治療するためのロスコビチンの使用
KR20150131155A (ko) 종양 약역학적 반응의 바이오마커
Liu et al. [Retracted] lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia
US20210252009A1 (en) Composition comprising flt3 inhibitor as effective ingredient for inhibiting drug resistance in chronic myelogenous leukemia
EP2979708A1 (en) Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient
WO2015134603A2 (en) Methods for treating cancer
US20230210849A1 (en) Cadherin-11 inhibitor formulation and its uses in immunotherapy
US20160287575A1 (en) Compositions and methods for the treatment of diseases involving hippo pathway
Colemon et al. ABL Kinases Modulate EZH2 Phosphorylation and Signaling in Metastatic Triple Negative Breast Cancer
US20100105745A1 (en) Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)